Search clinical trials for: Broadly HIV-1 Neutralizing Activity

Total 63754 results

Merck Sharp & Dohme LLC

Completed

A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)

HIV Infections | HIV-1
Wellness Wheel Medical Clinic
University of Saskatchewan; Saskatchewan Health Authority - Regina Area; CIHR...

Recruiting

Syphilis and HIV Point of Care Testing (POCT) in Saskatchewan (SHIVER)

HIV Infections | Syphilis

Canada
Cepheid

Completed

Clinical Evaluation of the Xpert® HIV-1 VL

Human Immunodeficiency Virus
ViiV Healthcare

Terminated

Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study

HIV Infections

United States
National Institutes of Health Clinical Center (CC)

Completed

Nucleic Acid Amplification Testing (NAT) of Blood Donors for HCV and HIV

HIV Infection | Hepatitis C

United States
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

More Than a Machine: Make Point-of-care HIV-1 Viral Load Testing Effective in Rural Uganda

HIV-1-infection

Uganda
National Institute of Allergy and Infectious Diseases...

Completed

VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...

HIV-1 Infection | HIV Antibodies | Neutralizing Antibody | Viral Load | Monoclonal Antibody

United States
MRC/UVRI and LSHTM Uganda Research Unit
Karolinska Institutet; Amsterdam Institute for Global Health and Development; University of Rwanda and other collaborators

Recruiting

East Africa Point of Care Viral Load Study (EAPoC-VL)

HIV | Viral Load | Point of Care Monitoring

Kenya, Uganda
National Institute of Allergy and Infectious Diseases...

Completed

A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID); Montefiore Medical... and other collaborators

Completed

A Study of the Safety and Antiretroviral Activity of 3BNC117

HIV-1 Infection

United States
Merck Sharp & Dohme LLC

Terminated

Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)

HIV Infections
University of Washington
University of Nairobi

Completed

Patient Actor Training to Improve HIV Services for Adolescents in Kenya (SPEED)

HIV/AIDS

Kenya
Johns Hopkins University
Centers for Disease Control and Prevention

Recruiting

Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC) (EHPOC)

HIV Infections | Syphilis

United States
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults

HIV-1

United States, Puerto Rico
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

HIV-1

United States, France, Spain, Portugal, Canada, United Kingdom, South Africa, Argentina, Brazil, Puerto Rico, Thailand, Netherlands, Romania
Frontier Biotechnologies Inc.

Recruiting

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects (ABL)

HIV-1-infection

United States
International AIDS Vaccine Initiative
Brigham and Women's Hospital; Fred Hutchinson Cancer Center; Rockefeller University

Active, not recruiting

Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

HIV-1-infection

United States, Uganda, Kenya, Rwanda, South Africa
Rockefeller University

Completed

3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption

HIV-1 Infection

United States
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.; Biocine

Completed

A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers

HIV Infections | HIV Seronegativity

United States, Puerto Rico
VGX Pharmaceuticals, LLC

Completed

Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group; Acute Infection and Early Disease Research Program

Completed

Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection

HIV Infections

United States, American Samoa, Australia
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults

HIV Infections

United States, Switzerland
University of Oxford
National Institute of Allergy and Infectious Diseases (NIAID); University of...

Completed

Tambua Mapema Plus - to Discover HIV Infection Early and Prevent Onward Transmission (TMP)

HIV Infections

Kenya
Ain Shams University

Not yet recruiting

Low Dose Atropine Eye Drops in Myopic Egyptian Children (LAMP)

Myopia Progression | Axial Length, Eye | Sclera Thickness

Egypt
National Cancer Institute (NCI)

Recruiting

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

Kaposi Sarcoma | Viral Associated Malignancies | EBV/KSHV-associated Lymphomas

United States
Ashwin Somasundaram
EMD Serono; University of North Carolina, Chapel Hill

Completed

Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

Gastric Adenocarcinoma | Metastasis | Esophageal Adenocarcinoma | HER-2 Gene Amplification

United States
ImmunityBio, Inc.

Active, not recruiting

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Triple Negative Breast Cancer

United States
Ottawa Hospital Research Institute

Completed

Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT) (REaCT-RETT)

Early-stage Breast Cancer

Canada
Qing XIe
Shanghai MedSci Healthcare Co. Ltd

Unknown

Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis

Hepatocellular Carcinoma | Hepatitis B, Chronic | Compensated Cirrhosis

China
Beijing Continent Pharmaceutical Co, Ltd.

Completed

Pharmacokinetic Interactions Between Hydronidone and Entecavir Capsules in Healthy Chinese Subjects

Hydronidone

China
Nanfang Hospital of Southern Medical University
JiangSu Chia-Tai Tianqin Pharmacy Co.Ltd

Unknown

Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy

Hepatitis B

China
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults

HIV Infections

United States, Brazil
Janssen Sciences Ireland UC

Completed

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

HIV-1

United States, South Africa, Ukraine, Kenya, Thailand, India, Romania, Uganda
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults

HIV Infections

United States
University of Kansas Medical Center
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Piloting At-birth Point of Care HIV Testing Strategies in Kenya

HIV Infections

United States, Kenya
Thrasher Research Fund
Centers for Disease Control and Prevention

Completed

Use of OraQuick for Screening HIV in Children Less Than Eighteen Months Old

HIV Antibody Testing

Zambia
Gilead Sciences

Completed

Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.

HIV | Human Immunodeficiency Virus | HIV-1

United States, Puerto Rico
Gilead Sciences

Completed

Safety Study of Once a Day ART and Opiate Substitute. (3OD)

HIV Infections

Germany
ANRS, Emerging Infectious Diseases
Institut National de la Santé Et de la Recherche Médicale, France; University... and other collaborators

Completed

Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention (PROMISE-EPI)

HIV-1

Burkina Faso, Zambia
Hospital Universitari Vall d'Hebron Research Institute
Gilead Sciences

Completed

Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla

HIV-1

Spain
Hospital Universitari Vall d'Hebron Research Institute
University Hospital, Ghent; IrsiCaixa

Completed

HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen

HIV-1

Spain
Gilead Sciences

Completed

Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada (RECOMB)

HIV-1

Spain
University of Aarhus
Aarhus University Hospital Skejby; Bandim Health Project; Abbott; Ministry of Health...

Completed

PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial (PIONA)

HIV-1

Guinea-Bissau
Tibotec Pharmaceuticals, Ireland

Completed

An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).

HIV-1

United States, Canada, France, Belgium, Germany, Spain, Argentina, Chile, Panama, Brazil, Puerto Rico, Thailand, Mexico, Australia
Mymetics Corporation
Institut Cochin; San Raffaele University Hospital, Italy; Kinesis Pharma B.V.; ... and other collaborators

Completed

Investigation of the Safety of an HIV-1 Vaccine Given Intra-muscularly and Intra-nasally to Healthy Female Subjects

HIV-1

Belgium
Janssen Pharmaceutica N.V., Belgium

Completed

Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets

HIV-1

United States, Spain
Merck Sharp & Dohme LLC

Completed

A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003)

HIV-1
Janssen Research & Development, LLC

Completed

Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets

HIV-1

United States
Janssen-Cilag Ltd.

Completed

Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients

HIV-1

Taiwan
Bristol-Myers Squibb

Completed

Korean Post-marketing Surveillance for Reyataz®

HIV-1

Korea, Republic of

Search clinical trials for: Broadly HIV-1 Neutralizing Activity

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations